- Two oral
presentations and three poster presentations will highlight Iomab-B
and Iomab-ACT CD45 targeted conditioning for bone marrow transplant
and CAR-T cellular therapy
NEW
YORK, Jan. 2, 2024 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today announced that five abstracts have been accepted for
presentation at the 2024 Tandem Meetings | Transplantation &
Cellular Therapy (TCT) Meetings of ASTCT® (American
Society for Transplantation and Cellular Therapy and
CIBMTR® (Center for International Blood and Marrow
Transplant Research) being held February
21 – 24, 2024 in San Antonio,
Texas. Two oral presentations will highlight results from
the positive Phase 3 SIERRA trial of Iomab-B
(131I-Apamistamab), representing 10 oral presentations
of the SIERRA results since they were first reported at the 2023
Tandem Meetings.
Sandesh Seth, Actinium's Chairman
and CEO, said, "We are excited to continue to build recognition for
Iomab-B and the SIERRA data with the transplant community at the
upcoming TCT meetings. Over the last year, we have highlighted to
the global transplant and hematology communities that an Iomab-B
led transplant improves outcomes for patients with high-risk
relapsed/refractory acute myeloid leukemia, including those with a
TP53 mutation, who have limited treatment options and poor outcomes
with current therapies. These results exemplify the unique
capabilities of targeted radiotherapy and its potent,
mutation-agnostic mechanism of action. We are highly encouraged by
the positive receptivity by the medical and scientific communities
to date and look forward to building on this momentum in 2024."
Oral Presentations:
Title: 131I-Apamistamab Improves Outcomes in Patients
65 Years and Older with Relapsed or Refractory AML
Date & Time: Saturday, February 24,
2024, at 11:45 AM
Title: Targeted Myeloablative Radiation Using
131I-Apamistamab Prior to Allogeneic Hematopoietic Cell
Transplant for Patients with R/R AML Results in Robust
Engraftment
Date & Time: Saturday, February 24,
2024, at 10:30 AM
Poster Presentations:
Dose-Response Demonstrated for Durable Complete Remission
Following High-Dose Targeted Radiation
with 131I-Apamistamab Prior to HCT in Patients with
R/R AML
Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves
Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell
Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal
CRS and Icans
131I-Apamistamab-Led Allogeneic Hematopoietic Cell
Transplant for Patients with TP53 Mutated R/R AML Results in
Significantly Improved Outcomes
The posters will be presented on Thursday, February 22, 2024, from 6:45 –
7:45 PM
About the TCT Tandem Meetings
The Tandem Meetings I Transplantation & Cellular
Therapy Meetings of ASTCT and CIBMTR are the combined annual
meetings of the American Society for Transplantation and
Cellular Therapy (ASTCT) and the Center for International
Blood & Marrow Transplant Research (CIBMTR). Administrators,
clinicians, data manager / clinical research professionals,
fellows-in-training, investigators, laboratory technicians,
MD/PhDs, nurses, nurse practitioners, pharmacists, physician
assistants, and other allied health professional attendees benefit
from a full scientific program that addresses the most timely
issues in hematopoietic cell transplantation and cellular
therapy.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other blood
cancers and next generation conditioning candidate Iomab-ACT to
improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma for
solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid
tumors, and several internal programs in solid tumors. Actinium
holds more than 220 patents and patent applications.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-announces-acceptance-of-five-abstracts-for-presentation-at-the-2024-tandem-meetings--transplantation--cellular-therapy-meetings-of-astct-and-cibmtr-302024287.html
SOURCE Actinium Pharmaceuticals, Inc.